XLV Stock Recent News

The market has shifted from tech to defensive stocks, with real estate and consumer staples outperforming due to tariffs and trade wars. US companies with high foreign sales exposure are struggling, while non-US stocks benefit from an international backlash against US tariffs. My buy list is narrowing, focusing on undervalued, high-conviction dividend growth stocks like Blackstone and Alphabet, despite market volatility.

President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.

President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC.  The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.

Tariffs have caused market turmoil, but long-term investors should consider recession-resistant REITs like CareTrust and Agree Realty to limit downside. CareTrust REIT has strong fundamentals, a low-leveraged balance sheet, and a growing portfolio, making it a solid choice during economic uncertainty. Agree Realty offers a recession-resistant portfolio with investment-grade tenants, a monthly dividend, and a strong balance sheet, positioning it well for market volatility.

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Health Care Select Sector SPDR ETF (XLV) is a passively managed exchange traded fund launched on 12/16/1998.

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients.

Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.

Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.

Bet on defensive and high-earnings growth sectors in this tumultuous April.

The Health Care Select Sector SPDR® Fund ETF is a highly representative ETF with $38.42 billion in AUM, a competitive expense ratio of 0.09%, and a dividend yield of 1.48%. Despite a 7% price drop since December, healthcare sector EPS expectations remain strong. XLV's forward P/E does not appear to show values significantly outside the historical distribution averages of the past 10 and 30 years.